© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
At a Glance: Asthma Biologics
As featured in Asthma Care Complications from our September issue. Swipe through the images for product descriptions and links to prescribing information.Â
Omalizumab (Xolair, Novartis/Genentech)
Initial U.S. approval: 2003
Indicated for: Moderate to severe persistent allergic asthma in patients 6 years of age or older not controlled by inhaled corticosteroids.
Contraindication: Severe hypersensitivity reaction to Xolair or any ingredient of Xolair.
Black Box Warning: risk of anaphylaxis.
Mepolizumab (Nucala, GSK)
Initial U.S. approval: 2015
Indicated for: Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Contraindications: History of hypersensitivity to mepolizumab or excipients in the formulation
Reslizumab (Cinqair, Teva)
Initial U.S. approval: 2016
Indicated for: Add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.
Contraindication: Known hypersensitivity toreslizumab or any of its excipients.
Black Box Warning: risk of anaphylaxis.
Dupilumab (Dupixent, Sonofi/Regeneron)
Initial U.S. approval: 2017
Indicated for: Add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma.
Contraindication: Known hypersensitivity to Dupixent or any of its excipients.